This page translates the Chinese website. Product availability and approved uses vary by country. Packaging and linked prescribing information may be in Chinese.
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name adalimumab injectionBrand Name QLETLI®English name Adalimumab InjectionChinese Pinyin Adamu Dankang Zhusheye
Ingredients
The principal ingredient is adalimumab.
Specifications
20 mg/0.4 mL; one prefilled syringe per carton; subcutaneous injection
Description
This product is a clear liquid prefilled in a syringe
Indications
Crohn's disease in children
plaque psoriasis in children
polyarticular juvenile idiopathic arthritis
Chinese Approval No.
Chinese Approval No. S20217001
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name adalimumab injectionBrand Name QLETLI®English name Adalimumab InjectionChinese Pinyin Adamu Dankang Zhusheye
Ingredients
The principal ingredient is adalimumab.
Specifications
40 mg/0.8 mL; one prefilled syringe per carton; subcutaneous injection
Description
This product is a clear liquid prefilled in a syringe
Indications
rheumatoid arthritis
ankylosing spondylitis
psoriasis
Crohn's disease
uveitis
Crohn's disease in children
plaque psoriasis in children
polyarticular juvenile idiopathic arthritis
Chinese Approval No.
Chinese Approval No. S20190038
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
POBEVCY®
bevacizumab injection · Avzivi® / Bevyx®
Therapeutic Area
tumor targeted therapy
Markets
China, United States, European Union, Brazil
Mechanism of action
Binds to human vascular endothelial growth factor (VEGF), inhibiting its interaction with its receptors and blocking angiogenesis signaling.
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
Drug name
Generic Name bevacizumab injectionBrand Name POBEVCY®English name Bevacizumab InjectionChinese Pinyin Beifazhu Dankang Zhusheye
Ingredients
The principal ingredient is bevacizumab.
Specifications
100 mg/4 mL; one vial per carton; intravenous injection
Description
This product is a sterile solution for intravenous injection, pH 5.9-6.3, clear to slightly opalescent, colorless to light brown liquid
Indications
metastatic colorectal cancer
Advanced, metastatic or recurrent non-small cell lung cancer
cervical cancer
recurrent glioblastoma
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
hepatocellular carcinoma
Chinese Approval No.
Chinese Approval No. S20210044
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
Drug name
Generic Name bevacizumab injectionBrand Name POBEVCY®English name Bevacizumab InjectionChinese Pinyin Beifazhu Dankang Zhusheye
Ingredients
The principal ingredient is bevacizumab.
Specifications
400 mg/16 mL; one vial per carton; intravenous injection
Description
This product is a sterile solution for intravenous injection, pH 5.9-6.3, clear to slightly opalescent, colorless to light brown liquid
Indications
metastatic colorectal cancer
Advanced, metastatic or recurrent non-small cell lung cancer
cervical cancer
recurrent glioblastoma
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
hepatocellular carcinoma
Chinese Approval No.
Chinese Approval No. S20210045
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
TOFIDENCE®
The World’s First Tocilizumab Biosimilar
tocilizumab injection
Therapeutic Area
autoimmune disease
Markets
China, United States, European Union, Switzerland, United Kingdom
Mechanism of action
Targets the interleukin-6 receptor (IL-6R), specifically binding to soluble and membrane-bound receptors (sIL-6R and mIL-6R) and inhibiting the signaling they mediate.
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
Drug name
Generic Name tocilizumab injectionBrand Name TOFIDENCE®English name Tocilizumab InjectionChinese Pinyin Tuozhu Dankang Zhusheye
Ingredients
The principal ingredient is tocilizumab.
Specifications
80 mg/4 mL; 1 or 4 vials per carton; intravenous infusion
Description
This product is colorless to light yellow clear liquid with slight opalescence.
Indications
rheumatoid arthritis
systemic juvenile idiopathic arthritis
cytokine release syndrome
Chinese Approval No.
Chinese Approval No. S20230003
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
Drug name
Generic Name tocilizumab injectionBrand Name TOFIDENCE®English name Tocilizumab InjectionChinese Pinyin Tuozhu Dankang Zhusheye
Ingredients
The principal ingredient is tocilizumab.
Specifications
200 mg/10 mL; 1 or 4 vials per carton; intravenous infusion
Description
This product is colorless to light yellow clear liquid with slight opalescence.
Indications
rheumatoid arthritis
systemic juvenile idiopathic arthritis
cytokine release syndrome
Chinese Approval No.
Chinese Approval No. S20240009
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
Drug name
Generic Name tocilizumab injectionBrand Name TOFIDENCE®English name Tocilizumab InjectionChinese Pinyin Tuozhu Dankang Zhusheye
Ingredients
The principal ingredient is tocilizumab.
Specifications
400 mg/20 mL; 1 or 4 vials per carton; intravenous infusion
Description
This product is colorless to light yellow clear liquid with slight opalescence.
Indications
rheumatoid arthritis
systemic juvenile idiopathic arthritis
cytokine release syndrome
Chinese Approval No.
Chinese Approval No. S20230001
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
BETAGRIN®
China Class 1 Innovative Drug
bevifibatide citrate injection
Therapeutic Area
cardiovascular disease
Markets
China
Mechanism of action
A peptide β3 integrin receptor inhibitor that targets both the platelet glycoprotein receptor αIIbβ3 (also known as IIb/IIIa) and the integrin receptor αvβ3.
Disclaimer: The following products are all prescription drugs and must be used under the guidance of a physician with experience in treating cardiovascular disease according to the instructions.
Drug name
Generic Name bevifibatide citrate injectionBrand Name BETAGRIN®English name Bevifibatide Citrate InjectionChinese Pinyin Juyuansuan Beiweibatai Zhusheye
Ingredients
The principal active ingredient is bevifibatide citrate.
Specifications
20 mg/10 mL, intravenously
Description
This product is colorless clear liquid
Indications
For use in patients with acute coronary syndrome undergoing percutaneous coronary intervention, including intracoronary stent placement, to reduce the risk of acute occlusion, stent thrombosis, no-reflow, and slow flow
Chinese Approval No.
Chinese Approval No. H20240030
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
STARJEMZA®USYMRO®
ustekinumab injection · STARJEMZA® / USYMRO®
Therapeutic Area
autoimmune disease
Markets
China, United States, European Union, United Kingdom
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name ustekinumab injectionBrand Name STARJEMZA®USYMRO®English name Ustekinumab InjectionChinese Pinyin Wusinu Dankang Zhusheye
Ingredients
The principal ingredient is ustekinumab.
Specifications
45 mg/0.5 mL; one prefilled syringe per carton; subcutaneous injection
Description
This product is a colorless to light yellow clear solution prefilled in a syringe
Indications
Adult plaque psoriasis
Crohn's disease
plaque psoriasis in children
Chinese Approval No.
Chinese Approval No. S20260031
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name ustekinumab injectionBrand Name STARJEMZA®USYMRO®English name Ustekinumab InjectionChinese Pinyin Wusinu Dankang Zhusheye
Ingredients
The principal ingredient is ustekinumab.
Specifications
90 mg/mL; one prefilled syringe per carton; subcutaneous injection
Description
This product is a colorless to light yellow clear solution prefilled in a syringe
Indications
Adult plaque psoriasis
Crohn's disease
plaque psoriasis in children
Chinese Approval No.
Chinese Approval No. S20260030
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name ustekinumab injectionBrand Name STARJEMZA®USYMRO®English name Ustekinumab Injection (Intravenous Infusion)Chinese Pinyin Wusinu Dankang Zhusheye
Ingredients
The principal ingredient is ustekinumab.
Specifications
130 mg/26 mL; one vial per carton; intravenous infusion
Description
This product is a sterile solution for intravenous infusion
Indications
Crohn's disease
Chinese Approval No.
Chinese Approval No. S20260027
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
IMMGOLIS™/IMMGOLIS INTRI™GOTENFIA®
First golimumab biosimilar in China
golimumab injection
Therapeutic Area
autoimmune disease
Markets
China, European Union, United States
Mechanism of action
Golimumab is an antibody targeting TNF-α that can specifically bind with high affinity to both soluble and transmembrane human TNF-α, blocking the binding of TNF-α to its receptor TNFR, thereby inhibiting the activity of TNF-α.
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name golimumab injectionBrand Name IMMGOLIS™/IMMGOLIS INTRI™GOTENFIA®English name Golimumab InjectionChinese Pinyin Gelimu Dankang Zhusheye
Ingredients
The principal ingredient is golimumab.
Specifications
50 mg/0.5 mL/tube/box, subcutaneous injection
Description
This product is a colorless to light yellow clear solution prefilled in a syringe
Indications
rheumatoid arthritis
ankylosing spondylitis
Chinese Approval No.
Chinese Approval No. S20260080
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name golimumab injectionBrand Name IMMGOLIS™/GOTENFIA®English name Golimumab InjectionChinese Pinyin Gelimu Dankang Zhusheye
Ingredients
The principal ingredient is golimumab.
Specifications
100 mg/mL/tube/box, subcutaneous injection
Description
This product is a colorless to light yellow clear solution prefilled in a syringe
Indications
rheumatoid arthritis
ulcerative colitis
Chinese Approval No.
It has been approved in Europe and the United States
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
golimumab injection (50 mg/4 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name golimumab injectionBrand Name IMMGOLIS INTRI™English name Golimumab InjectionChinese Pinyin Gelimu Dankang Zhusheye
Ingredients
The principal ingredient is golimumab.
Specifications
50 mg/4 mL/bottle/box, intravenous infusion
Description
This product is a sterile solution for intravenous infusion
Indications
rheumatoid arthritis
Chinese Approval No.
It has been approved for marketing in the United States, but has not yet been approved for marketing in China.
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
BAT2306
First approved secukinumab biosimilar globally
Secukinumab Injection
Therapeutic Area
Immunology
Markets
China
Mechanism of action
BAT2306 is an anti-human interleukin-17A (IL-17A) monoclonal antibody (IgG1κ) that selectively binds to IL-17A to inhibit its interaction with the IL-17 receptor, thereby suppressing the release of pro-inflammatory cytokines and chemokines. IL-17A is a cytokine produced during human inflammatory and immune responses and plays an important role in the pathogenesis of multiple autoimmune diseases. Increased numbers of IL-17A-secreting lymphocytes and elevated IL-17A levels have been found in the blood of patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
Drug name
Generic Name Scukinumab InjectionBrand Name BAT2306English name Scukinumab InjectionChinese Pinyin Sikuqiyou Dankang Zhusheye
Ingredients
The main ingredient is scukinumab.
Specifications
75mg（0.5ml）; subcutaneous injection
Description
Colorless to pale yellow liquid
Indications
Plaque psoriasis,
Psoriatic arthritis,
Ankylosing spondylitis
Chinese Approval No.
NMPA Approval No. S20260076
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
Drug name
Generic Name Scukinumab InjectionBrand Name BAT2306English name Scukinumab InjectionChinese Pinyin Sikuqiyou Dankang Zhusheye
Ingredients
The main ingredient is scukinumab.
Specifications
150mg（1ml）; subcutaneous injection
Description
Colorless to pale yellow liquid
Indications
Plaque psoriasis,
Psoriatic arthritis,
Ankylosing spondylitis
Chinese Approval No.
NMPA Approval No. S20260077
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-999-8703
More candidate drugs under development can be found in the R&D pipeline; for business cooperation and supply, please contact the business team.
